441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Executive Transition - Jeffrey Rona Departs; Charles Carter Appointed CFO
Ovid Therapeutics Inc. Annual Meeting Results - Director Election
Board Appointment - Anna Greka Joins Ovid Therapeutics Board of Directors
Reports Business Updates and First Quarter 2026 Financial Results
Annual Report to Security Holders
Other Events
Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
Q1
FY 2025
Q3
Q2
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
PREM14A
Correspondence
Submission Upload
S-8 POS